Previous 10 | Next 10 |
HAIFA, Israel, July 24, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that, its Board of Directors has approved a 1-for-10 reverse split ...
Bridgebio Pharma (NASDAQ: BBIO ) initiated with Buy rating and $42 (53% upside) price target at Goldman Sachs. Initiated with Buy rating and $38 price target at Jefferies. Initiated with Outperform rating and $49 price target at BMO. Initiated with Outperform rating and $34 price target at S...
Data will be jointly presented at the upcoming 2019 Radiation Injury Treatment Network (RITN) Workshop on July 31st HAIFA, Israel, July 17, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing...
HAIFA, Israel, July 02, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) , a leading regenerative medicine company developing novel placenta-based cell therapy products, today issued an update to its shareholders from its Chief Executive Officer, Yaky Ya...
HAIFA, Israel, July 02, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) , a leading regenerative medicine company developing novel placenta-based cell therapy products, today issued an update to its shareholders from its Chief Executive Officer, Yaky Ya...
HAIFA, Israel, June 24, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced the completion of the transition period of its Co-CEO structure and the ...
HAIFA, Israel, June 17, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (Nasdaq:PSTI) (TASE:PSTI) , a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced the Company has developed a serum-free formulation to support the manu...
Regenerative medicine has made steady progress over the last few years, but, with few exceptions, little of that progress has been reflected in appreciating stock prices. From an investor’s mindset, there should be a balanced perspective that weighs the promise of explosive revenue grow...
Introduction: The forgotten promises of stem cell research Since the discovery of stem cells, researchers have shown high ambitions in plans and projects to ensure better human health. And indeed, stem cells - which are basically universal human building blocks - can be a solution to many ex...
HAIFA, Israel, May 15, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, announced the publication of a peer-reviewed article in the European Journal of Vasc...
News, Short Squeeze, Breakout and More Instantly...
Pluristem Therapeutics Inc. Company Name:
PSTI Stock Symbol:
NASDAQ Market:
Pluristem Therapeutics Inc. Website:
HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholders from its Chief Executi...
As of July 26 , 2022 , Pluri ’s stock will trade under the symbol PLUR The new name reflects the Company ’s strategy to leverage its innovative 3D cell-based technology to a range of fields, developing cel...
The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration: https://pluristem.zoom.us/webinar/register/WN_kp_CwQQtR-aFtjAXrdiJpA HAIFA, Israel, Ju...